Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 1
2018 2
2019 3
2020 4
2021 3
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
The effect of disease modifying therapies on fatigue in multiple sclerosis.
Cruz Rivera S, Aiyegbusi OL, Piani Meier D, Dunne A, Harlow DE, Henke C, Kamudoni P, Calvert MJ. Cruz Rivera S, et al. Among authors: piani meier d. Mult Scler Relat Disord. 2023 Nov;79:105065. doi: 10.1016/j.msard.2023.105065. Epub 2023 Oct 10. Mult Scler Relat Disord. 2023. PMID: 37839365 Free article. Review.
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D, Rouyrre N, Ritter S, Kilaru A, Karlsson G, Giovannoni G, Kappos L. Cree BA, et al. Among authors: piani meier d. Mult Scler. 2022 Sep;28(10):1591-1605. doi: 10.1177/13524585221083194. Epub 2022 Apr 5. Mult Scler. 2022. PMID: 35380078 Free PMC article.
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, Cree BAC. Gold R, et al. Among authors: piani meier d. J Neurol. 2022 Sep;269(9):5093-5104. doi: 10.1007/s00415-022-11166-z. Epub 2022 May 31. J Neurol. 2022. PMID: 35639197 Free PMC article. Clinical Trial.
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
Hach T, Shakeri-Nejad K, Bigaud M, Dahlke F, de Micco M, Petricoul O, Graham G, Piani-Meier D, Turrini R, Brinkmann V, Nicoletti F. Hach T, et al. Among authors: piani meier d. J Interferon Cytokine Res. 2023 Jun;43(6):246-256. doi: 10.1089/jir.2022.0078. Epub 2022 Nov 29. J Interferon Cytokine Res. 2023. PMID: 36454249 Free PMC article. Review.
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Piani Meier D, Karlsson G, Tomic D, Wolf C, Dahlke F, Kappos L. Cree BA, et al. Among authors: piani meier d. Mult Scler. 2021 Sep;27(10):1564-1576. doi: 10.1177/1352458520971819. Epub 2020 Nov 18. Mult Scler. 2021. PMID: 33205682 Free PMC article. Clinical Trial.
Predicting risk of secondary progression in multiple sclerosis: A nomogram.
Manouchehrinia A, Zhu F, Piani-Meier D, Lange M, Silva DG, Carruthers R, Glaser A, Kingwell E, Tremlett H, Hillert J. Manouchehrinia A, et al. Among authors: piani meier d. Mult Scler. 2019 Jul;25(8):1102-1112. doi: 10.1177/1352458518783667. Epub 2018 Jun 18. Mult Scler. 2019. PMID: 29911467
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey.
Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño RR, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Ziemssen T, et al. Among authors: piani meier d. J Med Internet Res. 2021 Oct 6;23(10):e29558. doi: 10.2196/29558. J Med Internet Res. 2021. PMID: 34612826 Free PMC article.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold DL, Piani-Meier D, Bar-Or A, Benedict RH, Cree BA, Giovannoni G, Gold R, Vermersch P, Arnould S, Dahlke F, Hach T, Ritter S, Karlsson G, Kappos L, Fox RJ; EXPAND Clinical Investigators. Arnold DL, et al. Among authors: piani meier d. Mult Scler. 2022 Sep;28(10):1526-1540. doi: 10.1177/13524585221076717. Epub 2022 Mar 9. Mult Scler. 2022. PMID: 35261318 Free PMC article. Clinical Trial.
15 results